Your session is about to expire
← Back to Search
High-Intensity Treadmill Training for Multiple Sclerosis
N/A
Recruiting
Led By Brian D Schmit, PhD
Research Sponsored by Marquette University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up before training, 1-2 weeks after all training sessions, 6 months after all training sessions
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to help people with mild to moderate multiple sclerosis walk better by having them exercise intensely and practice balancing on a shaky treadmill. The combination of these activities is expected to improve their walking speed, endurance, and balance.
Who is the study for?
This trial is for adults aged 18-65 with multiple sclerosis (MS) who can walk 10 meters, have stable MS treatments and disease course, no severe medical conditions or recent heart attacks, and are not pregnant. They must be under 135kg in weight, able to follow commands, and commit to the training program.
What is being tested?
The study tests whether high-intensity gait training on a shaky treadmill improves walking speed, balance, and community mobility in people with MS. Participants will undergo different combinations of intensity levels and stability during treadmill exercises.
What are the potential side effects?
Potential side effects may include muscle soreness or fatigue due to high-intensity exercise. The shaky treadmill might cause dizziness or increase the risk of falls during training sessions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ before training, 1-2 weeks after all training sessions, 6 months after all training sessions
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~before training, 1-2 weeks after all training sessions, 6 months after all training sessions
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Changes in 6-minute walk test
Changes in Daily stepping activity
Changes in Functional Gait Assessment (FGA)
+1 moreSecondary study objectives
Changes in Activities-specific Balance Confidence (ABC) score
Changes in Average Duration of Stepping Bouts
Changes in Berg Balance Scale
+6 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: Moderate-Intensity With PerturbationsExperimental Treatment2 Interventions
30 sessions of moderate-intensity treadmill training will be conducted. Perturbations that disrupt balance will be applied during the training.
Group II: High-Intensity With PertubationsExperimental Treatment2 Interventions
30 sessions of high-intensity treadmill training will be conducted. Perturbations that disrupt balance will be applied during the training.
Group III: High-Intensity No PerturbationsExperimental Treatment1 Intervention
30 sessions of high-intensity treadmill training will be conducted on a stable treadmill.
Group IV: Moderate-Intensity No PerturbationsActive Control1 Intervention
30 sessions of moderate-intensity treadmill training will be conducted on a stable treadmill.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Multiple Sclerosis (MS) include disease-modifying therapies (DMTs) that target the immune system to reduce inflammation and slow disease progression, and symptomatic treatments like physical therapy and exercise. Intense exercise improves walking speed and endurance by enhancing cardiovascular fitness and muscle strength, while the shaky treadmill enhances balance by challenging the body's stability and proprioception.
These mechanisms are crucial for MS patients as they help mitigate mobility issues, reduce the risk of falls, and improve overall quality of life.
Find a Location
Who is running the clinical trial?
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,055 Previous Clinical Trials
2,731,723 Total Patients Enrolled
18 Trials studying Multiple Sclerosis
1,658 Patients Enrolled for Multiple Sclerosis
Indiana UniversityOTHER
1,039 Previous Clinical Trials
1,218,908 Total Patients Enrolled
1 Trials studying Multiple Sclerosis
15 Patients Enrolled for Multiple Sclerosis
Medical College of WisconsinOTHER
631 Previous Clinical Trials
1,181,808 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have no neurological diseases, seizures, nerve injuries in my legs, or brain injuries.I am between 18 and 65 years old and weigh less than 135kg.I haven't had a heart attack in the last month, my blood pressure is under control, I don't get dizzy standing up, and my diabetes is managed.I can walk and move my ankles, knees, and hips within a normal range.I can hear whispers and see clearly with glasses if needed.I can follow simple instructions.I have MS diagnosed by McDonald Criteria with a stable condition and no recent exacerbations.I am not pregnant nor planning to become pregnant, and I can use safety restraints.My MS treatments have been stable for 1 month, with no recent steroids or botulinum toxin injections above the knee.I can walk 10 meters on my own or with minimal help and don't have severe spasticity or exercise intolerance.I am medically stable and do not have severe illnesses that would limit my ability to exercise.I am not currently in physical therapy or supervised exercise programs.
Research Study Groups:
This trial has the following groups:- Group 1: Moderate-Intensity With Perturbations
- Group 2: Moderate-Intensity No Perturbations
- Group 3: High-Intensity No Perturbations
- Group 4: High-Intensity With Pertubations
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger